In the last trading session, 1.67 million I-Mab ADR (NASDAQ:IMAB) shares changed hands as the company’s beta touched 1.12. With the company’s per share price at $2.45 changed hands at $0.16 or 6.99% during last session, the market valuation stood at $193.40M. IMAB’s last price was a discount, traded about -9.39% off its 52-week high of $2.68. The share price had its 52-week low at $0.60, which suggests the last value was 75.51% up since then.
Analysts gave the I-Mab ADR (IMAB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IMAB as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. I-Mab ADR’s EPS for the current quarter is expected to be -0.04.
I-Mab ADR (NASDAQ:IMAB) trade information
Instantly IMAB was in green as seen at the end of in last trading. With action 87.02%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 188.24%, with the 5-day performance at 87.02% in the green. However, in the 30-day time frame, I-Mab ADR (NASDAQ:IMAB) is 175.28% up.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 28.36%. The 2025 estimates are for I-Mab ADR earnings to decrease by -31.25%.
IMAB Dividends
I-Mab ADR is expected to release its next quarterly earnings report in July.
CALIGAN PARTNERS LP holds the second largest percentage of outstanding shares, with 3.8067% or 3.37 million shares worth $5.64 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were abrdn Healthcare Investors and abrdn Healthcare Opportunities Fund . With 53.88 shares estimated at $0.13 million under it, the former controlled 0.07% of total outstanding shares. On the other hand, abrdn Healthcare Opportunities Fund held about 0.05% of the shares, roughly 43.74 shares worth around $0.11 million.
